ronapreve 120 mg/ml + 120 mg/ml solucion inyectable y para perfusion
roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 120mg/ml + 120mg/ml - por vial 11.10 ml - - casirivimab y imdevimab
ronapreve 300mg/2,5ml + 300mg/2,5ml solucion inyectable y para perfusion
roche farma (peru) s.a. - droguerÍa - casirivimab + imdevimab - solucion inyectable y para perfusion - 300mg +300mg - por vial 300.00 mg - - casirivimab y imdevimab
galafold 123 mg 14 cápsules dures
orserdu
stemline therapeutics b.v. - elacestrant - neoplasias de la mama - terapia endocrina - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.
barnascan 3000 mbq/ml 1 vial
fluorscan 3000 mbq/ml 1 vial
farna-fdg 3000 mbq/ml 1 vial
fluotracer 1110 mbq/ml 1 vial 11 ml
fluotracer 1110 mbq/ml 1 vial 25 ml